Revenue
2023
2024
2025
Zenas BioPharma, Inc. (ZBIO)
Price—Loading quote
Net income
2023
2024
2025
Free cash flow
2023
2024
2025
Total cash / debt
CashTotal debt
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | |
|---|---|---|---|
| Revenue | $10.0M | $5.0M | $50.0M |
| Research & development | $168.1M | $139.1M | $60.0M |
| Operating expenses | $393.1M | $168.9M | $87.1M |
| Operating income | −$383.1M | −$163.9M | −$37.1M |
| Net income | −$377.7M | −$157.0M | −$37.1M |
| Basic EPSper diluted share | -$8.44 | -$11.89 | -$24.25 |
| Diluted EPSper diluted share | -$8.44 | -$11.89 | -$24.25 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 18, 2026Form 4 | MOULDER LEON O JRChief Executive Officer | BuyCommon Stock · indirect | 60.0K | $16.88 | $1.01M | 96.9K |
| Apr 29, 2026Form 4 | MOULDER LEON O JRChief Executive Officer | BuyCommon Stock · indirect | 35.0K | $17.62 | $616.7K | 1.79M |
| Apr 28, 2026Form 4 | MOULDER LEON O JRChief Executive Officer | BuyCommon Stock · indirect | 25.0K | $18.02 | $450.5K | 1.75M |
| Mar 31, 2026Form 4 | Lu HongboDirector | BuyCommon Stock · indirect | 3.8K | $18.63 | $70.2K | 426.7K |
| Mar 31, 2026Form 4 | Kiselak Tomas +3Director | BuyCommon Stock · indirect | 150.0K | $20.00 | $3.00M | 2.36M |